TY - JOUR
T1 - Charting the course of electroconvulsive therapy
T2 - Where have we been and where are we headed?
AU - Rosenquist, Peter B.
AU - McCall, W. Vaughn
AU - Youssef, Nagy
N1 - Funding Information:
Dr. McCall receives research support from Merck & Co. and MECTA Corporation; has been a consultant for Merck & Co., Luitpold Pharmaceuticals, and Aetna Insurance; is on the speakers bureau for CME Outfitters; and receives royalties from Wolters Kluwer Health publishing. Dr. Youssef receives research support from the U.S. Department of Veterans Affairs and August Biomedical Research; and has received CME honoraria from the Georgia Department of Behavioral Health and Developmental Disabilities. The remaining author has disclosed no potential conflicts of interest, financial or otherwise.
Publisher Copyright:
© SLACK Incorporated.
PY - 2016/12
Y1 - 2016/12
N2 - Electroconvulsive therapy (ECT) is one of the oldest and best treatments for severe mental illness. A safe and highly effective option for treatment-resistant mood disorders, ECT can be a lifesaving treatment for people suffering from catatonia and acute suicidality. Less recognized are the benefits of ECT in the treatment of primary psychotic disorders, Parkinson’s disease, and status epilepticus. Evidence from multisite clinical trials in the past decade shows an evolving standard for the delivery of ECT to achieve and maintain remission and quality of life. Today, the optimal practice of ECT is defined by evidence-based treatment planning, including patient selection, choice of electrode placement and stimulus parameters, augmentation with pharmacotherapy, and the use of continuation/maintenance treatment. Research into biomarkers and neuroplasticity related to ECT response, as well as new investigational methods of delivering ECT, provide a glimpse into the future of this time-tested treatment.
AB - Electroconvulsive therapy (ECT) is one of the oldest and best treatments for severe mental illness. A safe and highly effective option for treatment-resistant mood disorders, ECT can be a lifesaving treatment for people suffering from catatonia and acute suicidality. Less recognized are the benefits of ECT in the treatment of primary psychotic disorders, Parkinson’s disease, and status epilepticus. Evidence from multisite clinical trials in the past decade shows an evolving standard for the delivery of ECT to achieve and maintain remission and quality of life. Today, the optimal practice of ECT is defined by evidence-based treatment planning, including patient selection, choice of electrode placement and stimulus parameters, augmentation with pharmacotherapy, and the use of continuation/maintenance treatment. Research into biomarkers and neuroplasticity related to ECT response, as well as new investigational methods of delivering ECT, provide a glimpse into the future of this time-tested treatment.
UR - http://www.scopus.com/inward/record.url?scp=85007502892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007502892&partnerID=8YFLogxK
U2 - 10.3928/02793695-20161208-08
DO - 10.3928/02793695-20161208-08
M3 - Article
C2 - 28001286
AN - SCOPUS:85007502892
SN - 0279-3695
VL - 54
SP - 39
EP - 43
JO - Journal of psychosocial nursing and mental health services
JF - Journal of psychosocial nursing and mental health services
IS - 12
ER -